Clinical Induced Pluripotent Stem Cell (iPSC) Reprogramming and Cell Differentiation
Over the past decade Allele Biotechnology has developed and patented (USPTO 10119150, 10155929) its proprietary iPSC reprogramming and differentiation methods that are based on non-integrating mRNA technology to enable the clinical use of iPSCs. mRNA based reprogramming allows for precise stoichiometric control of reagents and yields robust stem cells with unparalleled efficiency.
Our technical team has adapted all of our methods and reagents for cGMP production that is fully compatible with USFDA standards. These methods have been validated in our San Diego cGMP facility and can be used in our facility our out licensed for various projects.